Compare Kimberly Clark Corp (KMB) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Neurocrine Biosciences Inc — how do they compare? Kimberly Clark Corp trades at $108.57 (market cap $36.48B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Kimberly Clark Corp is far larger — about 2.2× Neurocrine Biosciences Inc's market cap, and Kimberly Clark Corp pays a 4.67% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| KMB | NBIX | |
|---|---|---|
Market Cap | $36.48B | $16.76B |
Sector | Consumer Staples | Health |
52-Week High | $134.81 | $185.50 |
52-Week Low | $93.05 | $123.10 |
Enterprise Value | $42.04B | $16.78B |
Dividend Yield | 4.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $109.68, up 0.94% with a bullish technical signal. The stock shows strong profitability with 11.79% net margin and 129.43% ROE, though Q2 2026 earnings missed estimates. Recent news highlights China market challenges and dividend stability. Current valuation metrics include P/E of 21.68 and P/S of 2.2, with analyst consensus price target of $113.20 suggesting modest upside potential from current levels.
KMB presents a balanced investment case with solid fundamentals offset by near-term headwinds. The company maintains strong brand positioning and dividend consistency, but faces execution risks from China market disruptions and consumer softness. Wall Street maintains cautious optimism with 61% hold ratings, indicating potential for gradual appreciation if operational challenges are managed effectively.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
